Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Rocket Pharmaceuticals, Inc. (RCKT : NSDQ)
 
 • Company Description   
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.

Number of Employees: 151

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.06 Daily Weekly Monthly
20 Day Moving Average: 788,629 shares
Shares Outstanding: 65.84 (millions)
Market Capitalization: $596.49 (millions)
Beta: 1.92
52 Week High: $49.66
52 Week Low: $7.57
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.94% -24.33%
12 Week -49.64% -45.36%
Year To Date -58.50% -50.65%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9 CEDARBROOK DRIVE
-
CRANBURY,NJ 08512
USA
ph: 609-659-8001
fax: 646-224-9585
investors@rocketpharma.com None
 
 • General Corporate Information   
Officers
Gaurav Shah - Chief Executive Officer and Director
Carlos Garcia-Parada - Chief Financial Officer
John C. Militello - VP; Finance; Senior Controller and Treasurer
Carsten Boess - Director
Pedro Granadillo - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 77313F106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 65.84
Most Recent Split Date: 1.00 (0.25:1)
Beta: 1.92
Market Capitalization: $596.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.70 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.40
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -3.08%
vs. Previous Quarter: 2.90%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -37.21
12/31/21 - -35.41
09/30/21 - -37.93
ROA
03/31/22 - -33.99
12/31/21 - -31.62
09/30/21 - -33.28
Current Ratio
03/31/22 - 15.68
12/31/21 - 17.69
09/30/21 - 17.36
Quick Ratio
03/31/22 - 15.68
12/31/21 - 17.69
09/30/21 - 17.36
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.34
12/31/21 - 7.05
09/30/21 - 7.54
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.05
12/31/21 - 0.04
09/30/21 - 0.04
Debt-to-Capital
03/31/22 - 4.39
12/31/21 - 4.04
09/30/21 - 3.79
 

Powered by Zacks Investment Research ©